» Articles » PMID: 30320595

Cognitive Performance After a One-Year Multidisciplinary Intensive Rehabilitation Program for Huntington's Disease: An Observational Study

Overview
Publisher Sage Publications
Date 2018 Oct 16
PMID 30320595
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies of physical therapy and multidisciplinary rehabilitation programs for Huntington's disease (HD) have shown improvements in gait function, balance, and physical quality of life. There is a gap in the literature on effects of cognitive interventions and the potential to improve cognitive performance.

Objective: To assess changes in cognitive performance among patients with early to middle stage HD as secondary analyses from a one-year multidisciplinary rehabilitation program. The program included cognitive stimulation as a non-specific cognitive intervention in addition to physical interventions.

Methods: A one-year rehabilitation program that included comprehensive neuropsychological assessments was completed by 31 out 37 participants with early to middle stages of HD. Socio-demographic and clinical information was recorded. A battery of neuropsychological tests was used to measure cognitive functions before and after the intervention. Descriptive statistics was used for sample characteristics. Paired sample t-tests and nonparametric Wilcoxon Signed ranked tests were used to compare cognitive measures at both time points.

Results: Scores on the Symbol Digit Modalities Test (SDMT) were significantly lower post intervention. There were no significant differences in all other measures. Scores on the Stroop color naming and California Verbal Learning Test-II (CVLT-II) long-term delayed recall tasks showed tendencies towards lower scores post intervention.

Conclusions: An intensive multidisciplinary rehabilitation program for patients with HD was generally well tolerated and feasible, with no indication of negative effects on cognition. Neuropsychological measures overall remained stable following an intensive multidisciplinary rehabilitation program, however continued progression of cognitive impairment was evident on the SDMT, suggesting that disease progression is not halted. Randomized controlled trials are needed to verify these findings.

Citing Articles

A randomized clinical trial to evaluate the efficacy of cognitive rehabilitation and music therapy in mild cognitive impairment in Huntington's disease.

Moreu-Valls A, Puig-Davi A, Martinez-Horta S, Kulisevsky G, Sampedro F, Perez-Perez J J Neurol. 2025; 272(3):202.

PMID: 39934473 DOI: 10.1007/s00415-025-12927-2.


Neurohabilitation of Cognitive Functions in Pediatric Epilepsy Patients through LEGO-Based Therapy.

Zaldumbide-Alcocer F, Labra-Ruiz N, Carbo-Godinez A, Ruiz-Garcia M, Mendoza-Torreblanca J, Naranjo-Albarran L Brain Sci. 2024; 14(7).

PMID: 39061442 PMC: 11274765. DOI: 10.3390/brainsci14070702.


The Role of Innovation Technology in the Rehabilitation of Patients Affected by Huntington's Disease: A Scoping Review.

Maggio M, Billeri L, Cardile D, Quartarone A, Calabro R Biomedicines. 2024; 12(1).

PMID: 38255146 PMC: 10813604. DOI: 10.3390/biomedicines12010039.


Update of Rehabilitation in Huntington's Disease: Narrative Review.

Kim K, Song M Brain Neurorehabil. 2023; 16(3):e28.

PMID: 38047100 PMC: 10689859. DOI: 10.12786/bn.2023.16.e28.


Cognition-oriented treatments and physical exercise on cognitive function in Huntington's disease: a systematic review.

Huynh K, Nategh L, Jamadar S, Stout J, Georgiou-Karistianis N, Lampit A J Neurol. 2022; 270(4):1857-1879.

PMID: 36513779 DOI: 10.1007/s00415-022-11516-x.


References
1.
Stout J, Andrews S, Glikmann-Johnston Y . Cognitive assessment in Huntington disease clinical drug trials. Handb Clin Neurol. 2017; 144:227-244. DOI: 10.1016/B978-0-12-801893-4.00019-5. View

2.
Thompson J, Cruickshank T, Penailillo L, Lee J, Newton R, Barker R . The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study. Eur J Neurol. 2012; 20(9):1325-9. DOI: 10.1111/ene.12053. View

3.
Tabrizi S, Scahill R, Owen G, Durr A, Leavitt B, Roos R . Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013; 12(7):637-49. DOI: 10.1016/S1474-4422(13)70088-7. View

4.
Dumas E, van den Bogaard S, Middelkoop H, Roos R . A review of cognition in Huntington's disease. Front Biosci (Schol Ed). 2013; 5(1):1-18. DOI: 10.2741/s355. View

5.
Tabrizi S, Reilmann R, Roos R, Durr A, Leavitt B, Owen G . Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2011; 11(1):42-53. DOI: 10.1016/S1474-4422(11)70263-0. View